The Seal of Excellence certifies the high-quality of the CLARITY proposal aimed at enhancing its data coverage, artificial intelligence approaches and analytics tools for drug discovery.
Barcelona, July 11th, 2019. Chemotargets recently submitted a Horizon 2020’s SME Instrument Phase 2 project proposal (880844) entitled “CLARITY: Intelligence and Discovery Platform for Predictive Pharmacology and Safety of Small Molecules” in which a second generation of the Chemotargets CLARITY® platform based on artificial intelligence approaches and state-of-the-art analytics tools was described. Following the evaluation by an international panel of independent experts, the proposal was scored as a high-quality project in a highly competitive evaluation process, meaning that the project passed all stringent Horizon 2020 assessment thresholds for the three award criteria (Excellence, Impact, and Quality and efficiency of implementation) required to receive funding from the EU budget Horizon 2020. Accordingly, the project CLARITY was awarded a Seal of Excellence, a high-quality certificate digitally signed by the Commissioners as a political commitment from the European Commission.
“We are absolutely delighted to receive this Seal of Excellence from the European Commission for the CLARITY proposal” commented Dr. Jordi Mestres, Chemotargets CEO. “We are committed to keep on building the capabilities in CLARITY® to accelerate the process of generating more efficacious and safer drugs and to become an indispensable tool from drug discovery to postmarketing surveillance”, added Dr. Mestres.
About Chemotargets CLARITY®
Chemotargets CLARITY® is an integrative analytics platform that consolidates chemistry, pharmacology, safety, and therapeutic intelligence (both known and predicted) of drugs and enables predictive pharmacology and safety of novel small molecules as well as metabolite generation and profiling. Multiple independent computational methods (including SAR, SAS and MLM) are used in a consensus approach to increase confidence in prediction results.
Based on an expertly curated set of 4.4 million in vitro pharmacology data points for 2.6 million molecules derived from patents, journals and public databases, CLARITY-v3.0 offers pharmacology models for 3,601 mechanism of action targets and off-targets. In addition, safety models based on 11.1 million post-marketing spontaneous reports from the US FDA Adverse Event Reporting System (FAERS) are also available for 520 safety events. Preclinical and clinical safety assessment is complemented with a predictive drug metabolism module based on a proprietary database of 8,961 drug-metabolite pairs collected manually from bibliographic sources. Finally, post-marketing safety signals identified with statistical analyses of carefully curated data from FAERS reports offer key elements for the pharmacovigilance surveillance of drugs.
All data, both known and predicted, can be inspected using state-of-the-art analytics tools. The forthcoming release, version 4.0, will include a purposely designed MedChem Explorer module to facilitate SAR analyses and purchasing of compound analogues by medicinal chemists from the catalogues of selected chemical providers. The updated FAERS Explorer module provides access to 50 years of reports (from 1969 to 2019, 15.1M) and offers numerous enhancements including safety comorbidity analyses and stratified age versus weight analyses, in addition to the identification of emergent and consolidated signals.
Latest publications related to or using results obtained with CLARITY:
- Mechanistic investigations of the liver toxicity of the free fatty acid receptor 1 agonist fasiglifam (TAK875) and its primary metabolites. Ackerson T. et al.. J Biochem Mol Toxicol. 2019, e22345.
- Assessing the Structural and Pharmacological Similarity of Newly Identified Drugs of Abuse to Controlled Substances Using Public Health Assessment via Structural Evaluation. Ellis CR. et al. Clin Pharmacol Ther. 2019, 106, 116-122.
- Dual Inhibitors of PARPs and ROCKs. Antolín AA, Mestres J. ACS Omega. 2018, 3, 12707-12712.
- Legacy data sharing to improve drug safety assessment: the eTOX project. Sanz F. et al. Nat Rev Drug Discov. 2017, 16, 811-812
- Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. Sultana J. et al. PLoS One. 2017, 12, e0187034.
About Chemotargets
Founded on March 2006 as a spin-off company from Dr. Mestres’ Research Group on Systems Pharmacology under the auspices of the IMIM Hospital del Mar Medical Research Institute. Chemotargets offers cutting-edge validated computational methodologies with top-market predictive performance. The company is currently recognized as a global leader in the provision of predictive analytics solutions to pharmaceutical and biotechnology companies and research institutions. Chemotargets’ goal is to help the biopharma industry fast-forward the process of bringing new medicines to market, speeding up drug discovery and development programs, and making them more cost-efficient.
For more information: e-mail clarity@chemotargets.com.
